Publications in collaboration with researchers from Hospital General Universitario Gregorio Marañón (64)

2023

  1. Opinion on the 2021 ESC guidelines on heart failure: a cross-sectional survey of 387 doctors

    REC: CardioClinics, Vol. 58, Núm. 1, pp. 7-15

  2. Akkermansia deficiency and mucin depletion are implicated in intestinal barrier dysfunction as earlier event in the development of inflammation in interleukin-10-deficient mice

    Frontiers in Microbiology, Vol. 13

2022

  1. Sex differences in the impact of frailty in elderly outpatients with heart failure

    Frontiers in Cardiovascular Medicine, Vol. 9

  2. Impact of blood pressure on management and prognosis of patients treated with sacubitril/valsartan

    REC: CardioClinics, Vol. 57, Núm. 2, pp. 116-122

  3. Frailty and prognosis of older patients with chronic heart failure

    Revista Espanola de Cardiologia, Vol. 75, Núm. 12, pp. 1011-1019

2021

  1. Current event of emerging viruses: Crimean-Congo hemorrhagic fever virus

    Gaceta Medica de Bilbao, Vol. 118, Núm. 1, pp. 49-53

  2. Initiation and titration of sacubitril/valsartan in different types of centers

    REC: CardioClinics, Vol. 56, Núm. 2, pp. 92-97

  3. Description of the genetic variants identified in a cohort of patients diagnosed with localized anal squamous cell carcinoma and treated with panitumumab

    Scientific Reports, Vol. 11, Núm. 1

2020

  1. Erratum: Isavuconazole is highly active in vitro against Candida species isolates but shows trailing effect (Clinical Microbiology and Infection (2018) 24(12) (1343.e1–1343.e4), (S1198743X18305214), (10.1016/j.cmi.2018.07.006))

    Clinical Microbiology and Infection

  2. Corrigendum to “Isavuconazole is highly active in vitro against Candida species isolates but shows trailing effect” [Clin Microbiol Infect 24 (12) (December 2018) 1343.e1-1343.e4](10.1016/j.cmi.2018.07.006)

    Clinical Microbiology and Infection

  3. Corrigendum to ‘Isavuconazole is highly active in vitro against Candida species isolates but shows trailing effect’ [Clinical Microbiology and Infection, Volume 24, (Issue 12) (December 2018) Pages 1343.e1-1343.e4](S1198743X18305214)(10.1016/j.cmi.2018.07.006)

    Clinical Microbiology and Infection

  4. Sacubitril/Valsartan is useful and safe in elderly people with heart failure and reduced ejection fraction. Data from a real-word cohort

    Revista Espanola de Geriatria y Gerontologia, Vol. 55, Núm. 2, pp. 65-69

  5. Long-term docosahexaenoic acid (DHA) supplementation in cystic fibrosis patients: a randomized, multi-center, double-blind, placebo-controlled trial

    Prostaglandins Leukotrienes and Essential Fatty Acids, Vol. 162

  6. Left Ventricular Ejection Fraction Recovery in Patients with Heart Failure and Reduced Ejection Fraction Treated with Sacubitril/Valsartan

    Cardiology (Switzerland), Vol. 145, Núm. 5, pp. 275-282

  7. Candida isolates causing candidemia show different degrees of virulence in Galleria mellonella

    Medical Mycology, Vol. 58, Núm. 1, pp. 83-92

2019

  1. Serratia marcescens colonization in preterm neonates during their neonatal intensive care unit stay

    Antimicrobial Resistance and Infection Control, Vol. 8, Núm. 1

  2. Safety of sacubitril/valsartan initiated during hospitalization: data from a non-selected cohort

    ESC Heart Failure, Vol. 6, Núm. 6, pp. 1161-1166

  3. Sacubitril/Valsartan in Daily Clinical Practice: Data from a Prospective Registry

    Journal of Cardiovascular Pharmacology, Vol. 73, Núm. 2, pp. 118-124

  4. Persistent Candidemia in adults: underlying causes and clinical significance in the antifungal stewardship era

    European Journal of Clinical Microbiology and Infectious Diseases, Vol. 38, Núm. 3, pp. 607-614

  5. Does the composition of polystyrene trays affect candida spp. biofilm formation?

    Medical Mycology, Vol. 57, Núm. 4, pp. 504-509